Author

Franco Scaldaferri

COMPARISON OF FECAL TRANSPLANTATION, FECAL TRANSPLANTATION WITH THE NOVEL UC DIET OR THE UC DIET ALONE FOR REFRACTORY MILD TO MODERATE ACTIVE ULCERATIVE COLITIS: THE CRAFT UC RANDOMIZED CONTROLLED TRIAL
COMPARISON OF FECAL TRANSPLANTATION, FECAL TRANSPLANTATION WITH THE NOVEL UC DIET OR THE UC DIET ALONE FOR REFRACTORY MILD TO MODERATE ACTIVE ULCERATIVE COLITIS: THE CRAFT UC RANDOMIZED CONTROLLED TRIAL

Franco Scaldaferri  et al.

IL-33/ST2 AND GUT MICROBIOTA AXIS CAN MODULATE THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS
IL-33/ST2 AND GUT MICROBIOTA AXIS CAN MODULATE THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS

Franco Scaldaferri  et al.

URINARY LITHOGENIC PROFILE AND GUT AND URINARY MICROBIOTA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
URINARY LITHOGENIC PROFILE AND GUT AND URINARY MICROBIOTA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Franco Scaldaferri  et al.

EMERGING ROLE OF IL-33/ST2 AND GUT MICROBIOTA AXIS IN THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS
EMERGING ROLE OF IL-33/ST2 AND GUT MICROBIOTA AXIS IN THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS

Franco Scaldaferri  et al.

TOWARDS A PERSONALIZED APPROACH IN ULCERATIVE COLITIS: ROLE OF OCTN1 IN PREDICTING DISEASE SEVERITY AND INDIVIDUAL RESPONSE TO THERAPY
TOWARDS A PERSONALIZED APPROACH IN ULCERATIVE COLITIS: ROLE OF OCTN1 IN PREDICTING DISEASE SEVERITY AND INDIVIDUAL RESPONSE TO THERAPY

Franco Scaldaferri  et al.

IMMUNE AND NON IMMUNE CHANGES FOLLOWING FMT IN EXPERIMENTAL COLITIS: EMERGING PATHWAYS OF FMT-DERIVED MUCOSAL HEALING
IMMUNE AND NON IMMUNE CHANGES FOLLOWING FMT IN EXPERIMENTAL COLITIS: EMERGING PATHWAYS OF FMT-DERIVED MUCOSAL HEALING

Franco Scaldaferri  et al.

THE POCER INDEX: APPLICATION OF A NOVEL ENDOSCOPIC SCORE IN A REAL-LIFE COHORT OF PATIENTS WITH CROHN'S DISEASE AFTER SURGERY
THE POCER INDEX: APPLICATION OF A NOVEL ENDOSCOPIC SCORE IN A REAL-LIFE COHORT OF PATIENTS WITH CROHN'S DISEASE AFTER SURGERY

Franco Scaldaferri  et al.

European consensus conference on faecal microbiota transplantation in clinical practice
European consensus conference on faecal microbiota transplantation in clinical practice

Franco Scaldaferri  et al.

THE SOLUTE CARRIER LC22A4/OCTN1AS A NOVEL IBD DETERMINANT AT THE MICROBE-HOST INTERFACE
THE SOLUTE CARRIER LC22A4/OCTN1AS A NOVEL IBD DETERMINANT AT THE MICROBE-HOST INTERFACE

Franco Scaldaferri  et al.

INFLIXIMAB BIOSIMILAR SWITCH IS SAFE AND EFFECTIVE, IT DOES NOT HAVE MAJOR PSYCHOLOGICAL IMPLICATIONS AND DOES NOT AFFET PHARMACOKINETICS IN A LARGE COHORT OF PATIENTS WITH IBD
INFLIXIMAB BIOSIMILAR SWITCH IS SAFE AND EFFECTIVE, IT DOES NOT HAVE MAJOR PSYCHOLOGICAL IMPLICATIONS AND DOES NOT AFFET PHARMACOKINETICS IN A LARGE COHORT OF PATIENTS WITH IBD

Franco Scaldaferri  et al.

SPECIFIC GUT MICROBIOTA SIGNATURES ARE ASSOCIATED WITH SYMPTOMATIC LACTOSE MALABSORPTION
SPECIFIC GUT MICROBIOTA SIGNATURES ARE ASSOCIATED WITH SYMPTOMATIC LACTOSE MALABSORPTION

Franco Scaldaferri  et al.

ENDOSCOPIC BALLOON DILATATION ASSOCIATED WITH BIOLOGICAL THERAPY IN CROHN’S DISEASE STRICTURES: A SINGLE CENTER EXPERIENCE
ENDOSCOPIC BALLOON DILATATION ASSOCIATED WITH BIOLOGICAL THERAPY IN CROHN’S DISEASE STRICTURES: A SINGLE CENTER EXPERIENCE

Franco Scaldaferri  et al.

HUMAN EXTRACHROMOSOMAL CIRCULAR DNA IS AN EMERGING BIOMARKER IN INFLAMMATORY BOWEL DISEASE
HUMAN EXTRACHROMOSOMAL CIRCULAR DNA IS AN EMERGING BIOMARKER IN INFLAMMATORY BOWEL DISEASE

Franco Scaldaferri  et al.

RADIOMICS COULD PREDICT SURGERY AT 10 YEARS IN CROHN’S DISEASE
RADIOMICS COULD PREDICT SURGERY AT 10 YEARS IN CROHN’S DISEASE

Franco Scaldaferri  et al.

European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies
European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies

Franco Scaldaferri  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION
EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION

Franco Scaldaferri  et al.

SERIAL FECAL MICROBIOTA INFUSIONS BY COLONOSCOPY FOR ACTIVE ULCERATIVE COLITIS: A FEASIBILITY, SAFETY AND TRANSLATIONAL MONOCENTRIC ITALIAN STUDY
SERIAL FECAL MICROBIOTA INFUSIONS BY COLONOSCOPY FOR ACTIVE ULCERATIVE COLITIS: A FEASIBILITY, SAFETY AND TRANSLATIONAL MONOCENTRIC ITALIAN STUDY

Franco Scaldaferri  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION: A SINGLE CENTRE REAL WORLD EXPERIENCE
EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB FORMULATION IN INFLAMMATORY BOWEL DISEASE PATIENTS IN CLINICAL REMISSION: A SINGLE CENTRE REAL WORLD EXPERIENCE

Franco Scaldaferri  et al.

REAL-LIFE VS TRIAL ACCESS TO BIOLOGICAL THERAPY DIFFERENCES: A 2019-2020 EXPERIENCE IN AN ITALIAN TERTIARY IBD CENTER
REAL-LIFE VS TRIAL ACCESS TO BIOLOGICAL THERAPY DIFFERENCES: A 2019-2020 EXPERIENCE IN AN ITALIAN TERTIARY IBD CENTER

Franco Scaldaferri  et al.

ORGANIC CATION TRANSPORTER (OCTN)-1 VARIANTS SHAPE INNATE IMMUNITY AND PREDICT INDIVIDUAL RESPONSE TO VEDOLIZUMAB IN ULCERATIVE COLITIS PATIENTS
ORGANIC CATION TRANSPORTER (OCTN)-1 VARIANTS SHAPE INNATE IMMUNITY AND PREDICT INDIVIDUAL RESPONSE TO VEDOLIZUMAB IN ULCERATIVE COLITIS PATIENTS

Franco Scaldaferri  et al.

Item 1 - 20 / 20
1